| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657203 | Clinical Gastroenterology and Hepatology | 2017 | 45 Pages |
Abstract
HBeAg seropositivity and hepatic steatosis contribute to persistent increases in ALT level in patients with CHB receiving suppressive antiviral treatment. ClinicalTrials.gov registration numbers: NCT00117676 and NCT00116805.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Ira M. Jacobson, Mary K. Washington, Maria Buti, Alexander Thompson, Nezam Afdhal, Robert Flisiak, Ulus Salih Akarca, Konstantin G. Tchernev, John F. Flaherty, Raul Aguilar Schall, Robert P. Myers, G. Mani Subramanian, John G. McHutchison,